According to information released by the Ministry of Health, Brazil has already achieved the milestone of producing over 50% of the medicines and supplies used by the Unified Health System (SUS). The announcement was made by Minister Padilha, highlighting the advancement of the national pharmaceutical industry.
This figure represents a significant step in reducing dependence on pharmaceutical and supply imports for Brazil's public health system. National production of medicines and supplies is fundamental to ensure availability and continuity of care within the SUS, while also strengthening the country's pharmaceutical production chain.
The Brazilian pharmaceutical industry has invested in expanding and modernizing its facilities, contributing to increased production capacity of essential medicines. This partial self-sufficiency allows greater control over the supply chain and reduces vulnerabilities related to fluctuations in the international market.
The strengthening of national medicine production benefits not only the SUS but also contributes to the country's economy, generating jobs and driving the Brazilian pharmaceutical industry. With this milestone already achieved, the goal is to continue expanding domestic production of medicines and supplies for greater independence.
